Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» DNL310
DNL310
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
BioSpace
Wed, 08/31/22 - 10:19 pm
Denali Therapeutics
clinical trials
DNL310
Hunter Syndrome
Denali Therapeutics Sees Positive Data in Trial for Enzyme Replacement Therapy
Marketwatch
Mon, 07/26/21 - 09:42 am
Denali Therapeutics
DNL310
enzymes
Hunter Syndrome
clinical trials